Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 133Squamous Cell Carcinoma of Head and Neck 76Lung Neoplasms 49Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 32Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 30Cholangiocarcinoma 28Esophageal Squamous Cell Carcinoma 26Carcinoma 24Neoplasms 23Ovarian Neoplasms 22Neoplasm Metastasis 22Small Cell Lung Carcinoma 21Carcinoma, Squamous Cell 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Transitional Cell 17Pancreatic Neoplasms 16Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

Nivolumab 11pembrolizumab 10Ipilimumab 9Cyclophosphamide 6tebentafusp 5Interleukin-2 4Blood Specimen Collection 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 3Melphalan 3Magnetic Resonance Spectroscopy 3relatlimab 2lenvatinib 2cemiplimab 2binimetinib 2aflibercept 2Surveys and Questionnaires 2Dacarbazine 2Crizotinib 2Carmustine 2Biopsy 2ulixertinib 1trametinib 1sargramostim 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Cisplatin × 1 year × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡